[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610635":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":38,"responsibleParty":64,"collaborators":11,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":11,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":11,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":11,"overallStatus":86,"whyStopped":11,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Beijing Suncadia Pharmaceuticals Co., Ltd","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"SHR-4658 Group","EXPERIMENTAL",null,[13],"Drug: SHR-4658 Injection.",{"label":15,"type":16,"description":11,"interventionNames":17},"SHR-4658 Placebo Group","PLACEBO_COMPARATOR",[18],"Drug: SHR-4658 Placebo Injection",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","SHR-4658 Injection.","SHR-4658 injection.",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"SHR-4658 Placebo Injection","SHR-4658 placebo injection.",[15],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Miao Guo","CONTACT","+86-0518-82342973","miao.guo.mg19@hengrui.com",{"name":36,"role":32,"phone":33,"phoneExt":11,"email":37},"Shuai Jiang","shuai.jiang.sj5@hengrui.com",[39],{"facility":40,"status":11,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Beijing Anzhen Hospital Capital Medical University","Beijing","Beijing Municipality","100029","China","CN",{"type":47,"coordinates":48},"Point",[49,50],116.39723,39.9075,{"lat":50,"lon":49},[53,57,61,63],{"name":54,"role":32,"phone":55,"phoneExt":11,"email":56},"Yang Lin","+86-010-64456045","linyang@anzhengcp.com",{"name":58,"role":32,"phone":59,"phoneExt":11,"email":60},"Shan Jing","+86-010-64456014","jingshan@anzhengcp.com",{"name":54,"role":62,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"name":58,"role":62,"phone":11,"phoneExt":11,"email":11},{"type":65,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100610635","phase-1-a-trial-of-shr-4658-in-healthy-volunteers-or-volunteers-with-elevated-blood-pressure-100610635",false,"NCT07230145","A Trial of SHR-4658 in Healthy Volunteers or Volunteers With Elevated Blood Pressure","A Double-Blind, Randomized, Dose-Escalating Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Dose SHR-4658 in Healthy Volunteers or Volunteers With Elevated Blood Pressure","Inclusion Criteria:\n\n1. Able and willing to provide a written informed consent.\n2. Blood pressure as defined in the protocol.\n3. Male or female，aged 18 to 55 years (inclusive).\n4. Meet the weight standard.\n\nExclusion Criteria:\n\n1. Known history or current clinically significant disease.\n2. Protocol-defined risk factors for disease.\n3. Participated in clinical trials of other drugs or medical devices.\n4. Pregnant or nursing women.",true,"ALL","18 Years","55 Years",{"count":78,"type":79},48,"ESTIMATED","INTERVENTIONAL",[82],"PHASE1","This is a clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and immunogenicity of single subcutaneous injection of SHR-4658 in healthy volunteers and volunteers with elevated blood pressure.",[85],"Heart Failure","NOT_YET_RECRUITING","2025-11-13",{"date":89,"type":90},"2025-11-17","ACTUAL",{"date":92,"type":79},"2025-11",{"date":94,"type":79},"2026-07",{"name":5,"class":6},1]